XOMA Royalty (XOMA) Operating Income (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Operating Income came in at -$480000.0 in Q1 2026, down 108.1% year-on-year from $5.9 million in Q1 2025, and up 80.96% quarter-over-quarter from -$2.5 million in Q4 2025.
XOMA Royalty (XOMA) Operating Income (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Operating Income across 16 years of filings, most recently posting -$480000.0 for Q1 2026.
- Operating Income for Q1 2026 came in at -$480000.0, down 108.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $272000.0 (up 101.01% YoY), and the FY2025 annual result was $6.7 million, up 116.71% from the prior year.
- Operating Income came in at -$480000.0 for Q1 2026 at XOMA Royalty, up from -$2.5 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $5.9 million in Q1 2025 to a low of -$19.9 million in Q4 2023.
- The 5-year median for Operating Income is -$5.8 million (2023), against an average of -$5.5 million.
- Across the five-year window, Operating Income plunged 392.49% in 2023 and jumped 184.65% in 2025, its largest moves.
- XOMA Royalty's Operating Income stood at -$6.2 million in 2022, then slumped by 221.0% to -$19.9 million in 2023, then jumped by 63.61% to -$7.3 million in 2024, then jumped by 65.24% to -$2.5 million in 2025, then surged by 80.96% to -$480000.0 in 2026.
- The last three Operating Income figures came in at -$480000.0 (Q1 2026), -$2.5 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -65.83 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | -480,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -480,000.00 |
| Dec 31, 2025 | -2.52 Mn |
| Sep 30, 2025 | -1.33 Mn |
| Jun 30, 2025 | 4.60 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | -7.25 Mn |
| Sep 30, 2024 | -15.64 Mn |
| Jun 30, 2024 | -10.08 Mn |
| Mar 31, 2024 | -7.00 Mn |
| Dec 31, 2023 | -19.93 Mn |
| Sep 30, 2023 | -5.79 Mn |
| Jun 30, 2023 | -5.96 Mn |
| Mar 31, 2023 | -10.17 Mn |
| Dec 31, 2022 | -6.21 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | -4.77 Mn |
| Mar 31, 2022 | -2.07 Mn |
| Dec 31, 2021 | 30.37 Mn |
| Sep 30, 2021 | -3.35 Mn |
| Jun 30, 2021 | -3.06 Mn |